MYSTERIOUS: 16 - What They Never Told You

Edinburgh University spin-out bags £9 million financing

Money includes a £2.5m Innovate UK grant to fund human clinical trials of its technology

Insider UK · Apr 6, 2022

Why Did FDA Pull Authorization For GSK-Vir's COVID-19 Therapy? Read Here

The U.S. health regulator said GlaxoSmithKline Plc (NYSE:GSK) and Vir Biotechnology Inc's (NASDAQ:VIR) antibody therapy was no longer authorized as a COVID-19 treatment. The decision was made as the CDC now estimates that the proportion of Covid-19 cases caused by BA.2 is above 50% nationwide. "Sotrovimab is no longer authorized to treat COVID-19 in any…

Benzinga · Apr 6, 2022

Governments want COVID vaccine developers to aim higher in hunt for better shots

As governments prepare to live with COVID-19, some are questioning how much to rely on drugmakers to adapt vaccines to ward off future virus variants amid signs of tension between companies and regulators over the best approach, according to several sources familiar with the matter.

Reuters · Mar 31, 2022

KTR showcases Telangana to pharma majors

Meets top leadership of Pfizer, Johnson & Johnson and GSK as part of his official tour to the US

The Hindu · Mar 26, 2022

LifeMine Therapeutics, GSK Ink $70M Drug Discovery, Development Pact

LifeMine Therapeutics Inc, a drug discovery startup that uses genetically-encoded small molecules, has partnered with GlaxoSmithKline plc (NYSE:GSK) to discover and develop drugs from fungal genomes.  GSK will bring three targets for LifeMine to run through its proprietary drug discovery platform, which scans for fungi that could be a match to create a…

Benzinga · Mar 23, 2022

Workers at GSK to vote on possible strike action over pay offer

Around 150 workers at the company's plant in Barnard Castle have rejected a 4% pay offer

Birmingham Post · Mar 21, 2022

GlaxoSmithKline says it will not start any new clinical trials in Russia

Pharma firm joins AstraZeneca and Pfizer in saying it will not enrol new patients into studies

The Guardian - UK · Mar 17, 2022

GSK halts new clinical trials in Russia but continues supply of medicines

The company is the latest drug-maker to take such steps, although the healthcare sector has not pulled out of the region entirely.

The Independent UK · Mar 17, 2022

Europe Kickstarts Reviewing AstraZeneca Application For Its COVID Antibody

European Medicines Agency has started reviewing AstraZeneca Plc's (NASDAQ:AZN) application for antibody-based COVID-19 therapy but gave no timeline for a conclusion. Infections from COVID-19 are still rising in parts of the world, including Europe. On Tuesday, China posted a steep jump in daily COVID-19 infections, with new cases more than doubling from a…

Benzinga · Mar 16, 2022

GSK/Vir Biotech's COVID-19 Antibody Associated With Resistance Mutations, New Research Shows

According to new research in Australia, some people have developed sotrovimab-resistant mutations following infusions with the GlaxoSmithKline Plc (NYSE:GSK) and Vir Biotechnology Inc (NASDAQ:VIR) monoclonal antibody with COVID-19 infection. Data shows that the mutations have been associated with a reduction by a factor of 100 to 297 in neutralization by sotrovimab. "These data show the persistence…

Benzinga · Mar 11, 2022